




QuikClot Control +™

For Use in
General Surgery





QuikClot Control+® Hemostatic Device

- QuikClot Control+™ is intended to be used on all patient populations where control of bleeding is required due to injuries and/or surgical wounds
- Suitable for both internal and external use
- May be left in place for up to 48 hours



Same Technique

- Same technique as standard gauze or laparotomy pads with more bleeding control in less time^{1,2}



Stronger Clot


- Robust clot forms quickly to deliver better bleeding control than standard gauze^{3,4}



Faster Bleeding Control

- Faster hemostasis may improve visualisation of the surgical field⁵
- Improved visualisation may allow for quicker identification of definitive repair needs

Mode of action




Safety and efficacy of a kaolin-impregnated hemostatic gauze in cardiac surgery: A randomized trial

Mubashir Mumtaz, MD,^a Richard B. Thompson, MD,^b Marc R. Moon, MD,^c Ibrahim Sultan, MD,^d T. Brett Reece, MD,^e William B. Keeling, MD,^f and Jacob DeLaRosa, MD^g

CENTRAL MESSAGE

QuikClot Control+ was superior to standard gauze in achieving hemostasis for mild (grade 1)/moderate (grade 2) cardiac surgery bleeding, with QuikClot Control+ subjects achieving hemostasis at more than 20% higher proportion at 5 and 10 minutes versus controls.



Subject proportions achieved hemostasis at 5 and 10 minutes: QCC+ (blue) and control (navy)

- QuikClot Control+
- Control

Safety and Efficacy of a Kaolin-Impregnated Hemostatic Gauze in Cardiac Surgery: a Randomized Trial

- 231 cardiac surgery patients
- Age > 18 years
- Mid to moderate bleeding
- Jun. 2020 – Sep. 2021
- 7 Study Sites

Randomization



- Cardiac surgery
 - CABG
 - Valve repair/replacement
 - Aortic aneurysm repair

No significant differences in safety or adverse events between treatment arms



Hemostasis achieved in 20.7% (5 mins) and 21.4% (10 mins) more QCC+ subjects compared to controls (P < .001)

Primary efficacy endpoint: hemostasis rate (i.e. Grade 0 bleed) through up to 10 mins of bleeding site application

Interval censored time-to-hemostasis assessments at 5 and 10 mins.

Variable	QCC+ (n = 153)	Standard Gauze (n = 78)	P-Value
Hemostasis rate at 5 mins.	121/153 (79.1%)	45/78 (58.4%)	<.001
Hemostasis rate at 10 mins.	137/153 (89.8%)	52/78 (68.4%)	<.001

Implications: QCC+ hemostatic gauze may be preferable to standard gauze for achieving hemostasis in mild to moderate cardiac surgery bleeding

QCC+ QuickClot Control +™, CABG: Coronary Artery Bypass Graft

Indications

QuikClot Control+ is indicated for temporary control of internal and external mild, moderate, severe, and traumatic bleeding due to injuries and/or surgical wounds.

Intended Purpose:

QuikClot Control+ is intended for control of internal and external bleeding.

Contraindications:

QuikClot Control+ is not indicated for intraluminal vascular use.

Intended Users:

Clinicians trained in the management of internal and external bleeding.

Patient Target Group:

QuikClot Control+ is intended to be used on all patient populations where control of bleeding is required due to injuries and/or surgical wounds.

Clinical Benefit:

The patient may expect the benefit of bleeding control at the site of application.

QuikClot™ Control+™ Product Offering

REF.	PRODUCT	DESCRIPTION	BOX QTY
4100	QuikClot™ Control +™ 5X5	12cmx12cm in 4 ply	10
4110	QuikClot™ Control +™ 8x8	20cmx20cm in 2 ply	10
4120	QuikClot™ Control +™ Z-Fold	7.6cm x 1.8m in 1 ply	10
4130	QuikClot™ Control +™ 12x12	30cmx30cm in 3 ply	10

References

1. Data on file at Teleflex. As compared to laparotomy pads.
2. Kheirabadi BS, Mace JE, Terrazas IB, et al. J Trauma. 2010;68(2):269-278. Pre-clinical study.
3. Garcia-Blanco J, Gegel B, Burgert J, et al. J Spec Oper Med. 2015;15(1):57-60.
4. Johnson D, Westbrook DM, Phelps D, et al. Am J Disaster Med. 2014;9(4):309-315.
5. Moss R. 2013; 1-39. <https://www.aorn.org/-/media/aorn/guidelines/tool-kits/medication-safety/management-of-surgical-hemostasisindependent-study-guide.pdf?la=en&hash=9FED3DF8BFDEF8B1C8D1899F8FC7BE79>. Accessed September 6, 2022

Teleflex, the Teleflex logo, QuikClot and QuikClot Control + are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative. Revised: 08/2024.

© 2024 Teleflex Incorporated. All rights reserved. MCI-101805 · REV 0 · 08 24 PDF

Distributed by:

Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com
United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com
South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

teleflex.com/...

Teleflex™
Empowering the future of healthcare